News | August 12, 2022
Aurobindo Pharma posts consolidated Q1FY23 PAT of Rs. 520.54 Cr
The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1097.78 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
